A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 [tasimelteon] and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia
Latest Information Update: 18 Nov 2014
At a glance
- Drugs Tasimelteon (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Acronyms JET5
- Sponsors Vanda Pharmaceuticals
- 20 May 2009 Results presented at APA 2009.
- 02 Dec 2008 Results published in the Lancet.
- 17 Nov 2006 Status change